Tesla's iPhone app now supports Live Activities for Supercharging
Tesla's latest iOS app update allows users to view their car's Supercharging progress on their phone's lock screen, Not A Tesla App reports.
The feature takes advantage of Apple's Live Activities feature, which gives apps the ability to display real-time updates on your lock screen, like showing your Uber is going to arrive, or when your ParkMobile parking meter is about to expire. In Tesla's case, it can keep you updated on the charging session and help alert you to move your car when it's done to avoid idle fees.
The Supercharger live activity shows how much time is left in the session, your current charge percentage, an estimated cost, the charge speed, and how much energy you've added. Currently, it does not show up if you're charging at home or non-Supercharger stalls.
Supercharger Live Activities is available now in the Tesla iOS app version 4.45.0 in the App Store. It's the latest major feature addition to the app since Tesla enabled Apple Watch digital key support last December.
In addition to the iOS update, Tesla is also rolling out a new feature for some of their newer EVs that can alert owners if they've forgotten their kid in the car. The new 'Child Left Alone' feature is only coming to Europe for now, specifically to the new Model 3 (mid 2023 and later), which include in-cabin radars. The hardware currently can sense people in the front seats in lieu of needing seat sensors, but now it's looking in the back seat, too. Tesla says it will roll out to other models and regions 'later.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
33 minutes ago
- Fast Company
The lab of the future: An artificial superintelligence for biology
The lab as we know it today is being transformed by how we think about medical research and drug discovery, as well as the intersection of artificial intelligence and biotechnology. As someone who has transitioned from a doctor to a tech CEO, I've witnessed firsthand how our mindset around medicine and innovation needs to evolve to keep pace with the accelerating changes in technology. In my journey, one of the most important lessons I've learned is: You can be too smart for your own good. It may sound counterintuitive, but when building a company or investing in new technologies, the smartest people often fall into the trap of overcomplicating things. A brilliant idea isn't always enough. You need the right people who can think creatively, take risks, and make it happen in the real world. For me, the mindset shift from doctor to CEO was about understanding that it's not just about medical knowledge; it's about building the right ecosystem to nurture that knowledge and turn it into real and transformative change. I believe that a crucial part of that ecosystem for my company, Owkin, is a new form of intelligence: a biological artificial superintelligence (BASI) to complement the ingenious human minds working with us. Next generation AI tools, like K Navigator, Owkin's agentic co-pilot for researchers, and K Pro for pharma, which is in the pipeline, will allow us to understand the full complexity of biology that has been beyond human understanding so far. This forms the backbone of Owkin's mission: We are creating the next-generation pharma focused on discovering cures and significantly enhancing pipeline value by developing a new intelligence system capable of decoding biological truths at scale. AI can fill the innovation gap left by pharma As the pharmaceutical industry increasingly focuses on a handful of blockbuster drugs, it's leaving behind many areas of medicine that are crucial for the future of healthcare. Too many diseases remain uncured as traditional pharma struggles to navigate the complexity of biology to augment care with efficient new molecules and diagnostics. From rare diseases to precision oncology, there's an innovation gap that AI is perfectly positioned to fill. AI can identify previously overlooked opportunities and streamline the development of treatments that are highly personalized and targeted. Unlike traditional pharmaceutical companies that are heavily reliant on large-scale, high-risk projects, AI companies can operate in a more agile, data-driven way. We can make smaller, more informed bets, leveraging machine learning and vast datasets to uncover insights that were once out of reach. This shift enables faster and more efficient drug discovery, with the added benefit of offering solutions for diseases that may not have attracted the attention of big pharma. Cell lines alone aren't going to work Most traditional biological research has been based on cell lines—cells removed from the human body and grown in petri dishes. But as we look to the future, there's a growing realization that cell lines, and other traditional research methods, are becoming outdated. While once a staple in biomedical research, they do not accurately replicate the complexity of human biology, and they fail to capture the diversity and variability that exists in real patients. AI-driven models are capable of moving beyond the limitations of cell lines by integrating data both from research done in cells and tissues removed from the body (in vitro) and from research done in living animals (in vivo). This validation approach, which incorporates multiple data types and sources, allows us to create more reliable and predictive models of human diseases. Science is advancing, and so is regulation. The FDA's recent announcement of plans to phase out animal testing in favor of 'more effective, human-relevant methods' means that we are entering an era where therapies can be tested on human tissue models from the very start. In collaboration with leading academic centers, Owkin has developed a patient-derived, lab-grown organoid (a mini version of a human organ), a breakthrough that brings us closer to faster, more accurate, and humane drug discovery. The combination of clinical data, genomic insights, and AI not only accelerates the development of new treatments but also increases their chances of success in clinical trials. The lab of the future The lab of the future will be one where AI is at the center, guiding discovery, improving precision, and increasing efficiency. Validation using real-world data will allow us to make better decisions and achieve higher rates of success. The traditional research process is being upended by these new technologies, and that's a good thing. The future of medicine will not just rely on human expertise, but on the power of AI and data to transform how we understand and treat disease. AI will deliver transformative therapies at an exponential scale, addressing the complexities of biology that traditional pharmaceutical approaches often cannot solve. Labs will become automated and serve as the ultimate playground for scientists, driving the future of drug discovery by harnessing the full potential of advanced AI systems. In these dynamic labs, organoids and agents will come together to work in synergy, allowing scientists to model and simulate human biology with greater accuracy. AI-driven technology will decipher biological patterns to identify the patients most likely to respond to specific treatments, significantly improving the chances of success in clinical trials and beyond. Seamlessly integrating these cutting-edge tools into the lab environment will transform the way we approach drug discovery, targeting diseases with a level of precision that was previously unimaginable. By pioneering the use of data, biology, and AI to decode the fundamental mechanics of disease and advance medical science, it will be possible to establish a foundation for the future of a 'positive singularity' in medicine. Through this innovative ecosystem, AI can revolutionize medicine. The time to innovate is now, and the possibilities are endless.
Yahoo
35 minutes ago
- Yahoo
Trump Says He Is Having Elon Musk Over At The White House Tomorrow For A Press Conference As Billionaire Exits Government: 'This Will Be His Last Day, But Not Really...'
On Thursday night, President Donald Trump said that he will host Elon Musk at the White House on Friday to mark the Tesla Inc. (NASDAQ:TSLA) CEO's departure from his official role leading the administration's Department of Government Efficiency. What Happened: In a post on Truth Social, Trump said, "I am having a Press Conference tomorrow at 1:30 P.M. EST, with Elon Musk, at the Oval Office. This will be his last day, but not really, because he will, always, be with us, helping all the way. Elon is terrific! See you tomorrow at the White House." Source: Truth Social Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — this is your last chance to become an investor for $0.80 per share. Nancy Pelosi Invested $5 Million In An AI Company Last Year — Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000. Why It's Important: Musk's move away from DOGE follows growing scrutiny over possible conflicts of interest and a drop in Tesla's sales. In an interview earlier this month, the billionaire acknowledged he may have devoted a bit too much time to politics, calling his engagement with government matters a time allocation issue. Musk's renewed focus on Tesla has reignited optimism among Wall Street analysts. Dan Ives of Wedbush Securities gave a bullish price target of $500, envisioning a potential $2 trillion valuation for the company. The Tesla CEO's decision to distance himself from DOGE also comes alongside his disapproval of Trump's $3.8 trillion spending plan, which he criticized as disappointing and detrimental to the efforts of DOGE. Photo Courtesy: RKY Photo on Read Next: Hasbro, MGM, and Skechers trust this AI marketing firm — Invest before it's too late. Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share! Send To MSN: Send to MSN UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Trump Says He Is Having Elon Musk Over At The White House Tomorrow For A Press Conference As Billionaire Exits Government: 'This Will Be His Last Day, But Not Really…' originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
E&E News
an hour ago
- E&E News
Elon Musk says goodbye. Sort of.
President Donald Trump held a news conference in the Oval Office on Friday to thank Elon Musk for his service leading the administration's government-slashing 'Department of Government Efficiency' operation. 'Americans owe him a great debt of gratitude,' Trump said as he praised the cuts made so far by the DOGE team. Musk and DOGE 'delivered a colossal change in the old ways of doing business in Washington,' Trump said. Musk 'had to go through the slings and the arrows, which is a shame, because he's an incredible patriot,' Trump said. 'The good news is that 90 percent of the country knows that, and they appreciate it, and they really appreciate what he did.' Advertisement Musk's time as a temporary special government employee has come to an end, the DOGE leader said as he stood behind the president for the nearly hourlong press conference.
